Coenzyme Q supplementation in pulmonary arterial hypertension

Redox Biology

Volumn 2, Issue 1, 2014, Pages 884-891

  Sharp, Jacqueline ^a   Farha, Samar ^a   Park, Margaret M ^a   Comhair, Suzy A ^a,b   Lundgrin, Erika L ^b   Tang, W H Wilson ^a,b   Bongard, Robert D ^c   Merker, Marilyn P ^c,d   Erzurum, Serpil C ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Coenzyme Q; Heart failure; Hemoglobin; Metabolism; Mitochondria; Pulmonary hypertension

Indexed keywords

ANTIBIOTIC AGENT; BRAIN NATRIURETIC PEPTIDE; GLUTATHIONE; HEMOGLOBIN; LACTIC ACID; PLACEBO; PREDNISONE; PYRUVIC ACID; UBIQUINONE; GLUTATHIONE DISULFIDE;

6 MINUTE WALK DISTANCE; ADULT; ARTERIAL PRESSURE; ARTICLE; BODY MASS; BORG DYSPNEA AND FATIGUE SCORE; CARDIOVASCULAR PARAMETERS; CELL MATURATION; CELL METABOLISM; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ERYTHROCYTE; FEMALE; GOUT; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART MITOCHONDRION; HEART PERFORMANCE; HEART RATE; HEMATOCRIT; HEMATOPOIESIS; HEME SYNTHESIS; HUMAN; LUNG VASCULAR RESISTANCE; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; METABOLIC PARAMETERS; MITOCHONDRION; OXIDATION REDUCTION REACTION; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RATING SCALE; RED CELL DISTRIBUTION WIDTH; SCORING SYSTEM; SUPPLEMENTATION; TREATMENT DURATION; TRICUSPID VALVE REGURGITATION; ADOLESCENT; CASE CONTROL STUDY; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; YOUNG ADULT; CELLULAR PARAMETERS; DRUG MECHANISM; HEART LEFT VENTRICLE ENDDIASTOLIC DIMENSION; HEART LEFT VENTRICLE ENDSYSTOLIC DIMENSION; HEART LEFT VENTRICLE MASS; HUMAN CELL; INTERVENTRICULAR ENDDIASTOLE SEPTAL THICKNESS; LACTATE BLOOD LEVEL; MITOCHONDRIAL MEMBRANE; POSTERIOR WALL THICKNESS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MITOCHONDRIA; UBIQUINONE; YOUNG ADULT;

EID: 84904887068     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.06.010     Document Type: Article

References (32)

1. Xu W., Erzurum S.C. Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension. Comprehensive Physiology 2011, 1(1):357-372. 10.1016/j.redox.2014.06.010.
2. Xu W., Koeck T., Lara A.R., Neumann D., DiFilippo F.P., Koo M., et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(4):1342-1347. 10.1016/j.redox.2014.06.010.
3. Fijalkowska I., Xu W., Comhair S.A., Janocha A.J., Mavrakis L.A., Krishnamachary B., et al. Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. American Journal of Pathology 2010, 176(3):1130-1138. 10.1016/j.redox.2014.06.010.
4. Archer S.L., Fang Y.H., Ryan J.J., Piao L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulmonary Circulation 2013, 3(1):144-152. 10.1016/j.redox.2014.06.010.
5. Archer S.L., Marsboom G., Kim G.H., Zhang H.J., Toth P.T., Svensson E.C., et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010, 121(24):2661-2671. 10.1016/j.redox.2014.06.010.
6. Krasuski R.A., Hart S.A., Smith B., Wang A., Harrison J.K., Bashore T.M. Association of anemia and long-term survival in patients with pulmonary hypertension. International Journal of Cardiology 2011, 150(3):291-295. 10.1016/j.redox.2014.06.010.
7. Ruiter G., Lankhorst S., Boonstra A., Postmus P.E., Zweegman S., Westerhof N., et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. European Respiratory Journal 2011, 37(6):1386-1391. 10.1016/j.redox.2014.06.010.
8. Hampole C.V., Mehrotra A.K., Thenappan T., Gomberg-Maitland M., Shah S.J. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. American Journal of Cardiology 2009, 104(6):868-872. 10.1016/j.redox.2014.06.010.
9. Decker I., Ghosh S., Comhair S.A., Farha S., Wilson Tang W.H., Park M., et al. High levels of zinc-protoporphyrin identify iron metabolic abnormalities in pulmonary arterial hypertension. Clinical and Translational Science 2011, 4(4):253-258. 10.1016/j.redox.2014.06.010.
10. Masri F.A., Comhair S.A.A., Dostanic-Larson I., Kaneko F.T., Dweik R.A., Arroliga A.C., et al. Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension. Clinical and Translational Science 2008, 1(2):99-106. 10.1016/j.redox.2014.06.010.
11. Hirano M., Garone C., Quinzii C.M. CoQ(10) deficiencies and MNGIE: two treatable mitochondrial disorders. Biochimica et Biophysica Acta 2012, 1820:625-631. 10.1016/j.redox.2014.06.010.
12. Langsjoen P.H., Langsjoen A.M. Overview of the use of CoQ10 in cardiovascular disease. BioFactors (Oxford, England) 1999, 9(2-4):273-284. 10.1016/j.redox.2014.06.010.
13. Littarru G.P., Tiano L., Belardinelli R., Watts G.F. Coenzyme Q (10), endothelial function, and cardiovascular disease. BioFactors (Oxford, England) 2011, 37(5):366-373. 10.1016/j.redox.2014.06.010.
14. Madmani M.E., Solaiman A.Y., Tamr Agha K., Madmani Y., Shahrour Y., Essali A., et al. Coenzyme Q10 for heart failure. Cochrane Database of Systematic Reviews 2013, 9. CD008684.
15. Simonneau G., Gatzoulis M.A., Adatia I., Celermajer D., Denton C., Ghofrani A., et al. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 2013, 62(25, Suppl.):D34-D41. 10.1016/j.redox.2014.06.010.
16. Littarru G.P., Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition (Burbank, Los Angeles County, CA) 2010, 26(3):250-254. 10.1016/j.redox.2014.06.010.
17. Brooks D., Solway S., Gibbons W.J. ATS statement on six-minute walk test. American Journal of Respiratory and Critical Care Medicine 2003, 167(9):1287. 10.1016/j.redox.2014.06.010.
18. Rudski L.G., et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography 2010, 23:685-713. 10.1016/j.redox.2014.06.010.
19. Lang R.M., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography 2005, 18:1440-1463. 10.1016/j.redox.2014.06.010.
20. Puwanant S., Park M., Popović Z.B., Tang W.H., Farha S., George D., et al. Ventricular geometry, strain, and rotational mechanics in pulmonary hypertension. Circulation 2010, 121(2):259-266. 10.1016/j.redox.2014.06.010.
21. Comhair S.A., Lewis M.J., Bhathena P.R., Hammel J.P., Erzurum S.C. Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease. American Journal of Respiratory and Critical Care Medicine 1999, 159(6):1824-1829. 10.1016/j.redox.2014.06.010.
22. Farha S., Asosingh K., Xu W., Sharp J., George D., Comhair S., et al. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood 2011, 117(13):3485-3493. 10.1016/j.redox.2014.06.010.
23. First drug to improve heart failure mortality in over a decade: coenzyme Q10 decreases all-cause mortality by half in randomized double blind trial. European Heart Journal 2013, 34(32):2496-2497.
24. Echtay K.S., Roussel D., St-Pierre J., Jekabsons M.B., Cadenas S., Stuart J.A., et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002, 415(6867):96-99. 10.1016/j.redox.2014.06.010.
25. Bowers R., Cool C., Murphy R.C., Tuder R.M., Hopken M.W., Flores S.C., et al. Oxidative stress in severe pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2004, 169(6):764-769. 10.1016/j.redox.2014.06.010.
26. Bonnet S., Michelakis E.D., Porter C.J., Andrade-Navarro M.A., Thébaud B., Bonnet S., et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: Similarities to human pulmonary arterial hypertension. Circulation 2006, 113(22):2630-2641. 10.1016/j.redox.2014.06.010.
27. Sharma S., Sud N., Wiseman D.A., Carter A.L., Kumar S., Hou Y., et al. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology 2008, 294(1):L46-L56. 10.1016/j.redox.2014.06.010.
28. Tang Z., Iqbal M., Cawthon D., Bottje W.G. Heart and breast muscle mitochondrial dysfunction in pulmonary hypertension syndrome in broilers (Gallus domesticus). Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology 2002, 132(3):527-540. 10.1016/j.redox.2014.06.010.
29. Michelakis E.D., McMurtry M.S., Wu X.C., Dyck J.R., Moudgil R., Hopkins T.A., Lopaschuk G.D., Puttagunta L., Waite R., Archer S.L. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002, 105:244-250. 10.1016/j.redox.2014.06.010.
30. Lundgrin E.L., Park M.M., Sharp J., Tang W.H., Thomas J.D., Asosingh K., Comhair S.A., DiFilippo F.P., Neumann D.R., Davis L., Graham B.B., Tuder R.M., Dostanic I., Erzurum S.C. Fasting 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Annals of the American Thoracic Society 2013, 10(1):1-9. http://www.ncbi.nlm.nih.gov/pubmed/23509326, 10.1016/j.redox.2014.06.010.
31. Molyneux S.L., Florkowski C.M., George P.M., Pilbrow A.P., Frampton C.M., Lever M., Richards A.M. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. Journal of the American College of Cardiology 2008, 52(18):1435-1441. 10.1016/j.redox.2014.06.010.
32. Bhagavan H.N., Chopra R.K. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 2007, 7(Suppl):S78-S88. 10.1016/j.redox.2014.06.010.